Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

BACKGROUND: Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the basis of in vitro activity, preclinical studies, and observational studies. Here, we report the results of a randomised trial to assess whether lopinavir–ritonavir improves outcomes in patients admitted to hospital...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535623/
https://www.ncbi.nlm.nih.gov/pubmed/33031764
http://dx.doi.org/10.1016/S0140-6736(20)32013-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535623/
https://www.ncbi.nlm.nih.gov/pubmed/33031764
http://dx.doi.org/10.1016/S0140-6736(20)32013-4

Ejemplares similares